

NEXT SCIENCE®

ASX ANNOUNCEMENT / MEDIA RELEASE
ASX: (NXS)

2023 Half Year Results Investor Briefing

Sydney, Australia Friday, 25 August 2023, Next Science Limited (ASX:NXS) (**Next Science** or the **Company**), a medical technology company focused on commercialising its proprietary XBIO™ suite of products to reduce the impact of biofilm-based infections in human health, advises that it intends to release its results for the half year ended 30 June 2023 on Thursday, 31 August 2023.

Next Science's Managing Director and CEO, I.V. Hall, will host an investor conference call and webcast at **11.00am (AEST) on Thursday, 31 August 2023** to discuss the results. The briefing is expected to last approximately 45 minutes inclusive of question time.

To pre-register for the call, please use the following link:

<https://registrations.events/direct/OCP60434>

To register to participate via webcast, please use the following link:

<https://webcast.openbriefing.com/nxs-hyr-2023/>

Next Science Investor Information

Next Science welcomes direct engagement and encourages shareholders and interested parties to visit the Next Science Investor Hub which provides additional background information, videos and a forum for stakeholders to communicate with each other and with the Company. Stakeholders can access the Investor Hub through the following link:

<https://investorhub.nextscience.com/announcements>

Further Information:

Martyn Jacobs

Head of Investor Relations

Phone: +61 412 785 180

Email: mjacobs@nextscience.com

Approved and authorised for release by the Managing Director and CEO, I.V. Hall.

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the company's primary focus is on the development and continued commercialisation of its proprietary XBIO™ technology to reduce the impact of biofilm-based infections in human health. XBIO™ is a unique, non-toxic technology with proven efficacy in eradicating both biofilm-based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its XBIO™ technology. For further information visit: www.nextscience.com